Milestones - About Us - 心通医疗

About Us

Milestones

2009-2013

Commenced early feasibility study for VitaFlow^® in 2009

2014

Commenced the pivotal clinical trial for VitaFlow^®

2015

Completed the first implantation of VitaFlow^® for pivotal clinical trial in China
Established Shanghai MicroPort CardioFlow Medtech Corporation
Commenced feasibility study for VitaFlow Liberty^®

2016

Completed the pivotal clinical trial enrollment for VitaFlow^® in China
VitaFlow^® was admitted into the “Green Path” for Innovative Medical Device by the NMPA

2017

Commenced the Registration Clinical Trial for VitaFlow Liberty^®in China
Achieved primary endpoints of the clinical trial in China for VitaFlow^®
Pre-IPO Investment(series B)

2018

Summitted VitaFlow^® registration application to the NMPA
Completed the first implantation of VitaFlow Liberty^® for registered clinical trial in China
VitaFlow Liberty^®was admitted into the “Green Path” for Innovative Medical Device by the NMPA

2019

Obtained NMPA approval for VitaFlow^®
Pre-IPO Investment(series C)

2020

Obtained approval for VitaFlow^® and Alwide^® in Argentina
Obtained approval for VitaFlow^®and Alwide^® in Thailand
Pre-IPO Investment (series D)

2021

CardioFlow was listed on the Main Board of the Hong Kong Stock Exchange
Obtained NMPA approval for VitaFlow Liberty^®, Alwide^®Plus and Angelguide^®
Completed the first overseas commercial implantation of VitaFlow^® in Argentina
Obtained approval for VitaFlow Liberty^® in Argentina

2022

Obtained approval for VitaFlow Liberty^®, Alwide^® Plus and Angelguide^® in Argentina
Completed the first implantation of VitaFlow Liberty^®in Colombia
Completed the first implantation of self-developed TMVR system in China
Obtained approval for Alwide^® Plus and Angelguide^® in Brazil
Obtained approval for Alwide^® Plus in Argentina

2023

Obtained approval for VitaFlow Liberty^® in Thailand, Russia, and Indonesia
Obtained approval for Alwide^®Plus in Thailand, Russia, Indonesia, Saudi Arabia, and Hong Kong, China
Completed the first implantation of VitaFlow Liberty^® in Thailand
Completed several pre-market human implantations of VitaFlow Liberty^® in Europe
Launched the first clinical application of VitaFlow^®III in China
Obtained NMPA approval for AccuSniper^TM

2024

Obtained NMPA approval for AnchorMan^® following the stake acquisition in CardioAdvent
Obtained EU CE certification for VitaFlow Liberty^® and completed first implants in six European countries
Completed first implants of VitaFlow Liberty^® in Chile, Indonesia, and Azerbaijan
Obtained approval for VitaFlow Liberty^® in Hong Kong (China), Saudi Arabia, Malaysia, South Korea, Turkey, and India
Obtained NMPA approval for VitaFlow Liberty^® Flex
Obtained approval for Alwide^® Plus in Mexico
Initiated pivotal clinical trial for AltaValve™ by affiliate 4C Medical

Privacy settings

This website may store cookies on your browser. Cookies are mostly used to make the website work asyou expect it to. No cookie will directly identify you, but it can give you a more personalized browsingexperience.

CardioFlow Medtech respects your privacy rights, so you can block some types of cookies. Technically non-essentialcookies and tracking mechanisms, that enable us to provide you with customized offers (marketingcookies), are only used if you have given prior consent to such use.

Strictly necessary cookies

Consent to marketing cookies

By clicking "Save", only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings. For more information, please see our Cookie Policy.